Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Journal of Cellular Biochemistry|August 10, 2005
Prospects: histone deacetylase inhibitorsMilos Dokmanovic, Paul A MarksAdvances in Clinical Chemistry|August 2, 2015
Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized MedicineMilos Dokmanovic, Wen Jin WuJournal of Cellular Biochemistry|December 4, 2002
Induction of senescence-associated growth inhibitors in the tumor-suppressive function of retinoidsIgor B Roninson, Milos DokmanovicExpert Opinion on Investigational Drugs|November 26, 2005
Histone deacetylase inhibitors: discovery and development as anticancer agentsPaul A Marks, Milos DokmanovicMolecular Cancer Research : MCR|October 24, 2007
Histone deacetylase inhibitors: overview and perspectivesMilos Dokmanovic, Cathy Clarke, Paul A MarksAntibody Therapeutics|May 3, 2021
Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicitiesYukinori Endo, Nishant Mohan, Milos Dokmanovic, et al.Antibody Therapeutics|September 15, 2018
Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiersNishant Mohan, Jiangsong Jiang, Milos Dokmanovic, et al.Cancer Research|June 17, 2010
pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformationDianne S Hirsch, Yi Shen, Milos Dokmanovic, et al.Cancer Biology & Therapy|August 13, 2002
Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genesMilos Dokmanovic, Bey-Dih Chang, Jing Fang, et al.Molecular Cancer Therapeutics|June 11, 2009
Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancerMilos Dokmanovic, Dianne S Hirsch, Yi Shen, et al.Pageof 3